Arbutus Biopharma Corp
ABUS$472M
Small CapNASDAQPharmaceutical PreparationsBiotechnology🇺🇸North AmericaWARMINSTER44 employees
Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Drugs in Pipeline
3
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
7wMarket Overview
Stock performance and key metrics
ABUS News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TKM-080301 | Phase 2 | Cancer | - | - |
ARB-001467 | Phase 2 | Hepatitis B, Chronic | - | - |
AB-729 | Phase 2 | Chronic Hepatitis b | - | - |
Cancer
1 drug in this indication
Chronic Hepatitis b
1 drug in this indication
Hepatitis B, Chronic
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply